Shots:
- The P-II trial assessed 5 doses of petrelintide (SC, QW) vs PBO for 42wks. in 493 overweight or obese pts (mean BMI of 37 kg/m²) with weight-related comorbidities
- Trial met its 1EP, with Q4W dose-escalated injections delivering significant weight loss across 5 arms after 28wks. & sustaining ~10.7% vs 1.7% mean reduction through Wk. 42, while 98% reached maintenance dose in the cohort achieving the greatest reduction; female pts lost considerably more weight than male pts
- Final ZUPREME-1 data, incl. a 9wk. safety follow-up will be presented in the future & help guide P-III trial design. Topline data from P-II (ZUPREME-2) trial in obesity/overweight with T2D are expected in H2’26, with a P-II trial of petrelintide + CT-388 planned later in 2026
Ref: Globenewswire | Image: Tenaya & Alnylam | Press Release
Related News: Roche Reports P-III (FENhance 1) Trial Data on Fenebrutinib in Relapsing Multiple Sclerosis (RMS)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
